FDA approves oral treatment for ulcerative colitis
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
X
FDA approves oral treatment for ulcerative colitis
https://pharmaphorum.com/news/fda-oral-treatment-ulcerative-colitis/
